Echinocandins: The newest class of antifungals

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,685 · see citing works

Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis

Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · see citing works

Echinocandin antifungal drugs

Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · see citing works

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 905 · see citing works

Anidulafungin versus Fluconazole for Invasive Candidiasis

Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · see citing works

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

van Burik, J. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 741 · see citing works

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · see citing works

Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy

Maertens, J., RAAD, I. I., Petrikkos, G. L., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A. L., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 651 · see citing works

Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638 · see citing works

Combination Antifungal Therapy for Invasive Aspergillosis

Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 607 · see citing works

Resistance to echinocandin-class antifungal drugs.

Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · see citing works

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494 · see citing works

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical <i>Candida</i> sp. Isolates

Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434 · see citing works

In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 389 · see citing works

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

Kurtz, M., Heath, I. B., Marrinan, J. A., Dreikorn, S., Onishi, J. C., & Douglas, C. M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 321 · see citing works

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

Bartizal, K. F., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311 · see citing works

A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis

Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308 · see citing works

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 293 · see citing works

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

Villanueva, A., Gotuzzo, E., Arathoon, E., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 290 · see citing works

Micafungin: A New Echinocandin

Chandrasekar, P. H., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/501020 · Cited by 255 · see citing works

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254 · see citing works

A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal Candidiasis

Krause, D. S., Simjee, A. E., van Rensburg, C. E. J., Viljoen, J., Walsh, T. J., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Clinical Infectious Diseases · doi:10.1086/423378 · Cited by 241 · see citing works

Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

Seibel, N. L., Schwartz, C. L., Arrieta, A. C., Flynn, P. M., Shad, A. T., Albano, E., Keirns, J. J., Lau, W. M., Facklam, D., Buell, D. N., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3317-3324.2005 · Cited by 241 · see citing works

Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis

Moudgal, V. V., Little, T., Boikov, D. A., & Vázquez, J. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.767-769.2005 · Cited by 241 · see citing works

Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

Walsh, T. J., Adamson, P. C., Seibel, N. L., Flynn, P. M., Neely, M. N., Schwartz, C. L., Shad, A. T., Kaplan, S. L., Roden, M. M., Stone, J. A., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4536-4545.2005 · Cited by 238 · see citing works

Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections

Benjamin, D. K., Driscoll, T., Seibel, N. L., Gonzalez, C. E., Roden, M. M., Kilaru, R., Clark, K., Dowell, J. A., Schranz, J., & Walsh, T. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.632-638.2006 · Cited by 209 · see citing works

The Echinocandins

Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205 · see citing works

A Randomized, Double-Blind, Parallel-Group, Dose-Response Study of Micafungin Compared with Fluconazole for the Treatment of Esophageal Candidiasis in HIV-Positive Patients

Wet, N. T. E. D., Llanos‐Cuentas, A., Suleiman, J. M. A. H., Baraldi, E., Krantz, E., Negra, M. D., & Diekmann-Berndt, H. (2004) · Clinical Infectious Diseases · doi:10.1086/423377 · Cited by 203 · see citing works

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201 · see citing works

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192 · see citing works

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology &amp; Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189 · see citing works

Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction

Hébert, M. F., Smith, H. E., Marbury, T. C., Swan, S. K., Smith, W. B., Townsend, R. W., Buell, D. N., Keirns, J. J., & Bekersky, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005279580 · Cited by 181 · see citing works

The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants

Heresi, G. P., Gerstmann, D. R., Reed, M. D., van den Anker, J. N., Blumer, J. L., Kovanda, L. L., Keirns, J. J., Buell, D. N., & Kearns, G. L. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000245103.07614.e1 · Cited by 178 · see citing works

Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia

Krause, D. S., Reinhardt, J. F., Vázquez, J. A., Reboli, A. C., Goldstein, B. P., Wible, M., & Henkel, T. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 177 · see citing works

Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

Louie, A., Deziel, M. R., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 163 · see citing works

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of <i>Candida</i> spp., Including 315 Isolates Resistant to Fluconazole

Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.11.5425-5427.2005 · Cited by 161 · see citing works

In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms

Nakai, T., Uno, J., Ikeda, F., Tawara, S., Nishimura, K., & Miyaji, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1376-1381.2003 · Cited by 157 · see citing works

In Vitro Activity of Micafungin (FK-463) against Candida spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies

Ernst, E. J., Roling, E. E., Petzold, C., Keele, D. J., & Klepser, M. E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3846-3853.2002 · Cited by 156 · see citing works

In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates

Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1068-1071.2003 · Cited by 152 · see citing works

Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

Hiemenz, J., Cagnoni, P. J., Simpson, D., Devine, S. M., Chao, N. J. A., Keirns, J. J., Lau, W. M., Facklam, D., & Buell, D. N. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1331-1336.2005 · Cited by 150 · see citing works

Acquired resistance to echinocandins in Candida albicans: case report and review

Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149 · see citing works

Emergence of a <i>Candida krusei</i> Isolate with Reduced Susceptibility to Caspofungin during Therapy

Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148 · see citing works

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis

Wet, N. T. E. D., Bester, A. J., Viljoen, J., Filho, F. A. B. D. O., Suleiman, J. M. A. H., Ticona, E., Llanos, E. A., Fisco, C., Lau, W. M., & Buell, D. N. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02427.x · Cited by 144 · see citing works

The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications

Wagner, C. C., Graninger, W., Presterl, E., & Joukhadar, C. (2006) · Pharmacology · doi:10.1159/000096348 · Cited by 123 · see citing works

The global epidemiology of invasive Candida infections—is the tide turning?

Hobson, R. P. (2003) · Journal of Hospital Infection · doi:10.1016/j.jhin.2003.08.012 · Cited by 123 · see citing works

Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit

Nguyen, T. H., Hoppe‐Tichy, T., Geiss, H. K., Rastall, A. C., Swoboda, S., Schmidt, J., & Weigand, M. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm125 · Cited by 118 · see citing works

Pharmacokinetics and Pharmacodynamics of Antifungals

Andes, D. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.007 · Cited by 115 · see citing works

The Candida albicans Cdr2p ATP‐binding cassette (ABC) transporter confers resistance to caspofungin

Schuetzer‐Muehlbauer, M., Willinger, B., Krapf, G., Enzinger, S., Presterl, E., & Kuchler, K. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03430.x · Cited by 111 · see citing works

Anidulafungin Does Not Require Dosage Adjustment in Subjects With Varying Degrees of Hepatic or Renal Impairment

Dowell, J. A., Stogniew, M., Krause, D., & Damle, B. D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297227 · Cited by 111 · see citing works

Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A. C., Flynn, P. M., Shad, A. T., Albano, E. A., Keirns, J. J., Buell, D. N., Gumbo, T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00398-07 · Cited by 110 · see citing works

Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A. L., Finquelievich, J. L., Barnes, R. A., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 105 · see citing works

Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits

Petraitienė, R., Petraitis, V., Groll, A. H., Candelario, M., Sein, T., Bell, A., Lyman, C. A., McMillian, C. L., Bacher, J., & Walsh, T. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2148 · Cited by 103 · see citing works

Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia

Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R., Fregeau, C., Hsu, V., & Louie, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-06 · Cited by 101 · see citing works

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

Kartsonis, N. A., Saah, A. J., Lipka, C. J., Taylor, A. F., & Sable, C. A. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.05.011 · Cited by 94 · see citing works

Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin

Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93 · see citing works

Population pharmacokinetics of micafungin in adult patients

Gumbo, T., Hiemenz, J., Ma, L., Keirns, J. J., Buell, D. N., & Drusano, G. L. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.09.018 · Cited by 76 · see citing works

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W. M., Facklam, D., Buell, D. N., & the FK463 South African Study Group (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02083.x · Cited by 75 · see citing works

Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations

Mistry, G. C., Migoya, E. M., Deutsch, P., Winchell, G. A., Hesney, M., Li, S., Bi, S., Dilzer, S. C., Lasseter, K. C., & Stone, J. A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303764 · Cited by 64 · see citing works

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety

Wiederhold, N. P., & Lewis, J. S. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1155 · Cited by 57 · see citing works

Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

Lewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn069 · Cited by 56 · see citing works

Micafungin

Carver, P. L. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d301 · Cited by 51 · see citing works

Killing Activity of Micafungin against Aspergillus fumigatus Hyphae Assessed by Specific Fluorescent Staining for Cell Viability

Watabe, E., Nakai, T., Matsumoto, S., Ikeda, F., & Hatano, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1995-1998.2003 · Cited by 50 · see citing works

A comparative evaluation of properties and clinical efficacy of the echinocandins

Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 48 · see citing works

Echinocandins: role in antifungal therapy, 2005

Zaas, A. K., & Alexander, B. D. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1657 · Cited by 45 · see citing works

A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

Vázquez, J. A., Schranz, J., Clark, K., Goldstein, B. P., Reboli, A. C., & Fichtenbaum, C. J. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817af47a · Cited by 45 · see citing works

Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center

Brielmaier, B. D., Casabar, E., Kurtzeborn, C. M., McKinnon, P. S., & Ritchie, D. J. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.1.64 · Cited by 42 · see citing works

Pharmacodynamic implications for use of antifungal agents

Lewis, R. E. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.05.004 · Cited by 38 · see citing works

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

Gumbo, T. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1bea3 · Cited by 35 · see citing works

Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

Lewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00715-08 · Cited by 23 · see citing works

Antifungals

Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511 · see citing works

Echinocandin Antifungal Drugs in Fungal Infections: A Comparison

Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371 · see citing works

Fungal natural products in research and development

Schüffler, A., & Anke, T. (2014) · Natural Product Reports · doi:10.1039/c4np00060a · Cited by 301 · see citing works

Echinocandins – structure, mechanism of action and use in antifungal therapy

Szymański, M., Chmielewska, S., Czyżewska, U., Malinowska, M., & Tylicki, A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2050224 · Cited by 281 · see citing works

Current Perspectives on Echinocandin Class Drugs

Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · see citing works

Quinoline-Based Antifungals

Musioł, R., Serda, M., Hensel-Bielówka, S., & Polański, J. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163966 · Cited by 251 · see citing works

Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs

Broyles, A. D., Banerji, A., Barmettler, S., Biggs, C. M., Blumenthal, K. G., Brennan, P. J., Breslow, R. G., Brockow, K., Buchheit, K. M., Cahill, K. N., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.08.006 · Cited by 248 · see citing works

Fungal keratitis: A review of clinical presentations, treatment strategies and outcomes

Sharma, N., Bagga, B., Singhal, D., Nagpal, R., Kate, A., Saluja, G., & Maharana, P. K. (2021) · The Ocular Surface · doi:10.1016/j.jtos.2021.12.001 · Cited by 235 · see citing works

Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens

Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230 · see citing works

Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Kelly, S. L., & Kelly, D. E. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0476 · Cited by 230 · see citing works

Antifungal peptides: To be or not to be membrane active

Rautenbach, M., Troskie, A. M., & Vosloo, J. A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.05.013 · Cited by 206 · see citing works

Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole

Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183 · see citing works

Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy

Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176 · see citing works

Peptide-based antifungal therapies against emerging infections

Matejuk, A., Leng, Q., Begum, M., Woodle, M. C., Scaria, P. V., Chou, S.-T., & Mixson, A. J. (2010) · Drugs of the Future · doi:10.1358/dof.2010.035.03.1452077 · Cited by 167 · see citing works

New Lead Structures in Antifungal Drug Discovery

Sheng, C., & Zhang, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480113 · Cited by 159 · see citing works

Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical

Colombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.02.001 · Cited by 157 · see citing works

Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation

Gómez‐López, A. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.037 · Cited by 145 · see citing works

Antifungal drugs: New insights in research & development

Nicola, A. M., Albuquerque, P., Paes, H. C., Fernandes, L., Costa, F. F., Kioshima, É. S., Abadio, A. K. R., Bocca, A. L., & Felipe, M. S. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.008 · Cited by 143 · see citing works

Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis.

Vella, A., De Carolis, E., Vaccaro, L., Posteraro, P., Perlin, D. S., Kostrzewa, M., Posteraro, B., & Sanguinetti, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00903-13 · Cited by 124 · see citing works

Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst

Sangalli-Leite, F., Scorzoni, L., Mesa-Arango, A. C., Casas, C., Herrero, E., Mendes‐Giannini, M. J. S., Rodrı́guez-Tudela, J. L., Cuenca‐Estrella, M., & Zaragoza, Ó. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.01.015 · Cited by 118 · see citing works

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

John, J., Loo, A. S., Mazur, S., & Walsh, T. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1671971 · Cited by 107 · see citing works

Use of Antifungal Combination Therapy: Agents, Order, and Timing

Johnson, M. D., & Perfect, J. R. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0018-6 · Cited by 103 · see citing works

Review on Current Status of Echinocandins Use

Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 108 · see citing works

Molecular Mechanisms of Action of Herbal Antifungal Alkaloid Berberine, in Candida albicans

Dhamgaye, S., Devaux, F., Vandeputte, P., Khandelwal, N., Sanglard, D., Mukhopadhyay, G., & Prasad, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104554 · Cited by 101 · see citing works

Nine Things Genomics Can Tell Us About Candida auris

Chybowska, A. D., Childers, D. S., & Farrer, R. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00351 · Cited by 96 · see citing works

Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient.

Garnacho‐Montero, J., Olaechea, P., Álvarez-Lerma, F., Álvarez-Rocha, L., Blanquer, J., Galván, B., Rodríguez, A. H., Zaragoza, R., Aguado, J. M., Mensa, J., et al. (2013) · PubMed · Cited by 97 · see citing works

Ibrexafungerp: A novel oral glucan synthase inhibitor

Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91 · see citing works

New therapeutic options for onychomycosis

Gupta, A. K., & Simpson, F. C. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.681779 · Cited by 86 · see citing works

What do we know about the biology of the emerging fungal pathogen of humans Candida auris?

Ruiz, G. B., & Lorenz, A. (2020) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 83 · see citing works

Pharmacologic therapy of mycotic keratitis

Sahay, P., Singhal, D., Nagpal, R., Maharana, P. K., Farid, M., Gelman, R. A., Sinha, R., Agarwal, T., Titiyal, J. S., & Sharma, N. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.02.007 · Cited by 83 · see citing works

Biofilms and Chronic Wounds: Pathogenesis and Treatment Options

Shen, A., Taha, M. R., Ghannoum, M. A., & Tyring, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217784 · Cited by 92 · see citing works

Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall

Liu, W., Yuan, L., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00748 · Cited by 80 · see citing works

Novel antifungal agents: a patent review (2011 – present)

Castelli, M. V., Butassi, E., Monteiro, M. C., Svetaz, L. A., Vicente, F., & Zacchino, S. A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.876993 · Cited by 72 · see citing works

Overview of treatment options for invasive fungal infections

Pound, M. W., Townsend, M. L., DiMondi, V. P., Wilson, D. T., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 69 · see citing works

Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates

Simitsopoulou, M., Pešková, P., Tasina, E., Katragkou, A., Kyrpitzi, D., Velegraki, A., Walsh, T. J., & Roilides, E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02541-12 · Cited by 66 · see citing works

Antimicrobial peptides: from discovery to developmental applications

Zhang, Q. (2025) · Applied and Environmental Microbiology · doi:10.1128/aem.02115-24 · Cited by 64 · see citing works

Fungal BGCs for Production of Secondary Metabolites: Main Types, Central Roles in Strain Improvement, and Regulation According to the Piano Principle

Zhgun, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311184 · Cited by 65 · see citing works

Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis

Kubiak, D. W., Porter, J., McDonnell, A., Delgado-Flores, J. O., Mui, E., Baden, L. R., & Marty, F. M. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.005 · Cited by 62 · see citing works

Invasive fungal infections in transplant recipients

Vázquez, J. A., Miceli, M. H., & Alangaden, G. J. (2013) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936113491936 · Cited by 63 · see citing works

Pneumocystis jirovecii pneumonia in people living with HIV: a review

McDonald, E. G., Afshar, A., Assiri, B., Boyles, T. H., Hsu, J. M.-Y., Khuong, N. B., Prosty, C. J., So, M., Sohani, Z. N., Butler‐Laporte, G., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-22 · Cited by 65 · see citing works

Antifungal Treatment of Small Animal Veterinary Patients

Foy, D. S., & Trepanier, L. A. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2010.07.006 · Cited by 61 · see citing works

Aspergillosis: an Update on Clinical Spectrum, Diagnostic Schemes, and Management

Kanaujia, R., Singh, S., & Rudramurthy, S. M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00461-5 · Cited by 63 · see citing works

Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives

Branda, F., Petrosillo, N., Ceccarelli, G., Giovanetti, M., VITO, A. D., Madeddu, G., Scarpa, F., & Ciccozzi, M. (2025) · Infectious Disease Reports · doi:10.3390/idr17040091 · Cited by 68 · see citing works

Antifungal drug resistance in Candida: a special emphasis on amphotericin B

Ahmady, L., Gothwal, M., Mukkoli, M. M., & Bari, V. K. (2024) · Apmis · doi:10.1111/apm.13389 · Cited by 58 · see citing works

Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review

Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 53 · see citing works

Novel antifungal agents: a patent review (2013 - present)

Castelli, M. V., Derita, M., & López, S. N. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1261113 · Cited by 53 · see citing works

Past, Present, and Future of Antifungal Drug Development

Shukla, P. K., Singh, P., Yadav, R. K., Pandey, S., & Bhunia, S. S. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_4 · Cited by 46 · see citing works

Opportunities and challenges of RiPP-based therapeutics

Pfeiffer, I. P.-M., Schröder, M.-P., & Mordhorst, S. (2024) · Natural Product Reports · doi:10.1039/d3np00057e · Cited by 45 · see citing works

Iron Assimilation during Emerging Infections Caused by Opportunistic Fungi with emphasis on Mucorales and the Development of Antifungal Resistance

Stanford, F. A., & Voigt, K. (2020) · Genes · doi:10.3390/genes11111296 · Cited by 43 · see citing works

Activities of Systemically Administered Echinocandins against In Vivo Mature Candida albicans Biofilms Developed in a Rat Subcutaneous Model

Kucharíková, S., Sharma, N., Spriet, I., Maertens, J. A., Dijck, P. V., & Lagrou, K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02288-12 · Cited by 43 · see citing works

Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges

Παπαδοπούλου, Α., Kaloyannidis, P., Yannaki, E., & Cruz, C. C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.005 · Cited by 41 · see citing works

Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance

Mehta, D., Saini, V., & Bajaj, A. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00151b · Cited by 41 · see citing works

Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Kim, H. Y., Baldelli, S., Märtson, A., STOCKER, S. L., Alffenaar, J. C., Cattaneo, D., & Marriott, D. J. E. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000931 · Cited by 39 · see citing works

Invasive Candidiasis in the Elderly: Considerations for Drug Therapy

Dekkers, B. G. J., Veringa, A., Marriott, D. J. E., Boonstra, J., van der Elst, K. C. M., Doukas, F. F., McLachlan, A. J., & Alffenaar, J. C. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0576-9 · Cited by 37 · see citing works

High-Throughput Screen for Identifying Small Molecules That Target Fungal Zinc Homeostasis

Simm, C., Luan, C.-H., Weiss, E., & O'Halloran, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025136 · Cited by 34 · see citing works

PDR-like ABC systems in pathogenic fungi

Moréno, A., Banerjee, A., Prasad, R., & Falson, P. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2019.09.002 · Cited by 33 · see citing works

Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents

Hussain, M. K., Ahmed, S., Khan, A., Siddiqui, A. J., Khatoon, S., & Jahan, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115010 · Cited by 34 · see citing works

Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation

Caldara, M., & Marmiroli, N. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.06.023 · Cited by 31 · see citing works

The future of fungal susceptibility testing

Posteraro, B., & Sanguinetti, M. (2014) · Future Microbiology · doi:10.2217/fmb.14.55 · Cited by 31 · see citing works

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

Chandrasekar, P. H., & Miceli (2012) · Infection and Drug Resistance · doi:10.2147/idr.s22587 · Cited by 31 · see citing works

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics

Ashbee, H. R., & Gilleece, M. H. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.146 · Cited by 30 · see citing works

Oxadiazolylthiazoles as novel and selective antifungal agents

Hagras, M., Salama, E. A., Sayed, A. M., Abutaleb, N. S., Kotb, A., Seleem, M. N., & Mayhoub, A. S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112046 · Cited by 30 · see citing works

An expanded cell wall damage signaling network is comprised of the transcription factors Rlm1 and Sko1 in Candida albicans

Heredia, M. Y., Ikeh, M. A. C., Gunasekaran, D., Conrad, K. A., Filimonava, S., Marotta, D. H., Nobile, C. J., & Rauceo, J. M. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008908 · Cited by 29 · see citing works

Investigational drugs for onychomycosis

Gupta, A. K., & Simpson, F. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.840289 · Cited by 28 · see citing works

Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis

Maximova, N., Schillani, G., Simeone, R., Maestro, A., & Zanon, D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0534-7 · Cited by 27 · see citing works

Identification of New Antifungal Agents Targeting Chitin Synthesis by a Chemical-Genetic Method

Li, Y., Sun, H., Zhu, X., Bian, C., Wang, Y., & Si, S. (2019) · Molecules · doi:10.3390/molecules24173155 · Cited by 29 · see citing works

Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?

Martens‐Lobenhoffer, J., Rupprecht, V., & Bode‐Böger, S. M. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.05.033 · Cited by 27 · see citing works

Endogenous nitric oxide accumulation is involved in the antifungal activity of Shikonin against Candida albicans

Liao, Z., Yan, Y., Dong, H., Zhu, Z., Jiang, Y., & Cao, Y. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.87 · Cited by 28 · see citing works

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

Kullberg, B. J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.-A., Garbino, J., Yan, J. L., Aram, J. A., Capparella, M. R., Conte, U., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx116 · Cited by 27 · see citing works

Total synthesis and structure–activity relationships of new echinocandin-like antifungal cyclolipohexapeptides

Yao, J., Liu, H., Zhou, T., Chen, H., Miao, Z., Sheng, C., & Zhang, W. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.054 · Cited by 26 · see citing works

Metabolic Engineering of Filamentous Fungi

Meyer, V. (2021) · Metabolic Engineering · doi:10.1002/9783527823468.ch20 · Cited by 26 · see citing works

Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs

Hon, K. E., Chan, V. P. Y., Leung, A. K. C., Leung, K. K. Y., & Hui, W. F. (2024) · Drugs in Context · doi:10.7573/dic.2023-9-2 · Cited by 25 · see citing works

Organic Antifungal Drugs and Targets of Their Action

Maksimov, A. I., Balandina, S. Y., Topanov, P. A., Mashevskaya, I. V., & Chaudhary, S. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666210108122622 · Cited by 24 · see citing works

Interactions between antifungal and antiretroviral agents

Hughes, C. A., Foisy, M., & Tseng, A. L.-I. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003752694 · Cited by 24 · see citing works

The Use of Antifungal Therapy in Neonatal Intensive Care

Testoni, D., Smith, P. B., & Benjamin, D. K. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.008 · Cited by 24 · see citing works

Identification of Genes inCandida glabrataConferring Altered Responses to Caspofungin, a Cell Wall Synthesis Inhibitor

Rosenwald, A., Arora, G. S., Ferrandino, R. M., Gerace, E. L., Mohammednetej, M., Nosair, W., Rattila, S., Subic, A. Z., & Rolfes, R. J. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.032490 · Cited by 22 · see citing works

A Review: Antimicrobial Therapy for Human Pythiosis

Medhasi, S., Chindamporn, A., & Worasilchai, N. (2022) · Antibiotics · doi:10.3390/antibiotics11040450 · Cited by 23 · see citing works

Efficient Bioconversion of Echinocandin B to Its Nucleus by Overexpression of Deacylase Genes in Different Host Strains

Shao, L., Li, J., Liu, A., Chang, Q., Lin, H., & Chen, D. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.02792-12 · Cited by 23 · see citing works

Echinocandins as Biotechnological Tools for Treating Candida auris Infections

Cândido, E. D. S., Affonseca, F., Cardoso, M. H. E. S., & Franco, O. L. (2020) · Journal of Fungi · doi:10.3390/jof6030185 · Cited by 22 · see citing works

Treatment with echinocandins during continuous renal replacement therapy

de Molina, F. J. G., Martínez-Alberici, M., & Ferrer, R. (2014) · Critical Care · doi:10.1186/cc13803 · Cited by 21 · see citing works

Microbial lipopeptides: their pharmaceutical and biotechnological potential, applications, and way forward

Sreelakshmi, K. P., Madhuri, M., Swetha, R., Rangarajan, V., & Roy, U. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-03908-0 · Cited by 21 · see citing works

Transcriptional regulation of the caspofungin-induced cell wall damage response in Candida albicans

Heredia, M. Y., Gunasekaran, D., Ikeh, M. A. C., Nobile, C. J., & Rauceo, J. M. (2020) · Current Genetics · doi:10.1007/s00294-020-01105-8 · Cited by 21 · see citing works

Antifungal therapy for newborn infants with invasive fungal infection

Clerihew, L., & McGuire, W. L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003953.pub3 · Cited by 21 · see citing works

Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats

Sun, P., & Tong, Z. (2014) · Medical Mycology · doi:10.1093/mmy/myu060 · Cited by 21 · see citing works

Antifungal resistance, combinations and pipeline: oh my!

Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 19 · see citing works

Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell–Dependent Pathology in Invasive Aspergillosis

Amarsaikhan, N., Sands, E. M., Shah, A., Abdolrasouli, A., Reed, A. K., Slaven, J. E., Armstrong-James, D. P. H., & Templeton, S. P. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700078 · Cited by 20 · see citing works

Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungin

Toutounji, M., Tokajian, S. T., & Khalaf, R. A. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.02.008 · Cited by 19 · see citing works

Current efforts and the potential of nanomedicine in treating fungal keratitis

Gratieri, T., Gelfuso, G. M., Lopez, R. F. V., & Souto, E. B. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.19 · Cited by 20 · see citing works

Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations

Albanell‐Fernández, M. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01461-5 · Cited by 19 · see citing works

Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi

Chen, X., Duan, H. D., Hoy, M. J., Koteva, K. K., Spitzer, M., Guitor, A. K., Puumala, E., Fiebig‐Comyn, A., Hu, G., Yiu, B., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.036 · Cited by 23 · see citing works

A Genome-Wide Screening of Potential Target Genes to Enhance the Antifungal Activity of Micafungin in Schizosaccharomyces pombe

Zhou, X., Ma, Y., Fang, Y., gerile, W., Jaiseng, W., Yamada, Y., & Kuno, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065904 · Cited by 19 · see citing works

The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review

Jendoubi, A., Pressiat, C., de Roux, Q., Lesne-Hulin, A., Ghaleh, B., Tissier, R., Kohlhauer, M., & Mongardon, N. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107078 · Cited by 18 · see citing works

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

Auzinger, G. M., Playford, E. G., Graham, C. N., Knox, H. N., Weinstein, D. L., Kantecki, M., Schlamm, H. T., & Charbonneau, C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1143-1 · Cited by 18 · see citing works

Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies

Perrine-Walker, F. M. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00739-9 · Cited by 19 · see citing works

Hyperactive TORC 1 sensitizes yeast cells to endoplasmic reticulum stress by compromising cell wall integrity

Ahmed, K., Carter, D. E., & Lajoie, P. (2019) · FEBS Letters · doi:10.1002/1873-3468.13463 · Cited by 17 · see citing works

Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris

Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10100698 · Cited by 16 · see citing works

Progress in the Stereoselective Synthesis Methods of Pyrrolidine-Containing Drugs and Their Precursors

Smolobochkin, А. V., Gazizov, A. S., Appazov, N. O., Sinyashin, O. G., & Burilov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011158 · Cited by 19 · see citing works

Ste11p MEKK signals through HOG, mating, calcineurin and PKC pathways to regulate the FKS2 gene

Wang, X., Sheff, M. A., Simpson, D. M., & Elion, E. A. (2011) · BMC Molecular Biology · doi:10.1186/1471-2199-12-51 · Cited by 16 · see citing works

Quantitative Analysis of Candida Cell Wall Components by Flow Cytometry with Triple-Fluorescence Staining

Nogueira, F., Istel, F., Jenull, S., Walker, L. A., Gow, N. A., & Lion, T. (2017) · Journal of Microbiology and Modern Techniques · doi:10.15744/2575-5498.2.101 · Cited by 17 · see citing works

Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents

Choi, H., Kim, J. H., Seong, H., Lee, W. J., Jeong, W., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., Kim, Y. K., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.039 · Cited by 15 · see citing works

Echinocandins in the management of invasive fungal infections, part 2

Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p2 · Cited by 54 · see citing works

Echinocandins in the management of invasive fungal infections, part 1

Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p1 · Cited by 86 · see citing works

A comparative evaluation of properties and clinical efficacy of the echinocandins

Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 48 · see citing works

Emerging echinocandins for treatment of invasive fungal infections

Turner, M., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49 · see citing works

Echinocandins: Ask Not What They Can Do for Esophageal Candidiasis--Ask What Studies of Esophageal Candidiasis Can Do for Them

Darouiche, R. O. (2004) · Clinical Infectious Diseases · doi:10.1086/423391 · Cited by 4 · see citing works